Just been looking into something that's been getting a lot of buzz lately. The whole obesity drug trend has basically created this interesting investment angle that most people aren't really talking about yet.

So here's what's happening: with Oprah backing weight loss medications like Mounjaro, Wegovy, and Ozempic, we're seeing a genuine shift in how people view these treatments. It's not just celebrity endorsement noise anymore—there's real money flowing into this sector. And if you're looking to play this trend, there are actually some solid ETF options worth examining.

First up is the iShares US Healthcare Providers ETF (IHF). This one's been around for a while and tracks healthcare providers specifically. It's got holdings in UnitedHealth Group, CVS Health, Cigna, and Humana—companies that are all positioning themselves in the wellness space. The expense ratio sits at 0.40%, which is pretty reasonable. It's more of a broad healthcare play, so it's less volatile than some alternatives.

Then there's the Obesity ETF (SLIM) from Janus Henderson. This is the more direct play on the obesity drug boom. SLIM specifically focuses on companies involved in obesity treatment across multiple sectors—pharmaceuticals, medical devices, weight loss programs, the whole ecosystem. The fund holds significant positions in Novo Nordisk (the Wegovy and Ozempic maker) and DexCom, plus companies like Herbalife. You're looking at a more concentrated bet here, which means higher risk but also higher potential upside if the trend accelerates.

The third option is VanEck Pharmaceutical ETF (PPH). This one's interesting because it gives you exposure to the pharma companies driving the obesity drug innovation. Eli Lilly's been a major winner with Mounjaro gaining serious traction. Novo Nordisk's semaglutide portfolio is another key holding. PPH has a low expense ratio of 0.36%, making it cost-effective.

What's worth noting: all three of these ETFs are essentially betting on the same underlying trend—that obesity treatment is becoming mainstream medicine rather than a niche market. The obesity ETF play is probably the most direct if you want concentrated exposure, while IHF and PPH give you more diversification.

The real question is whether this trend has legs or if it's just hype. Based on what we're seeing with pharmaceutical adoption rates and the amount of capital flowing in, I'd say this is more than just a passing fad. If you're thinking about adding exposure to this sector, these three are worth putting on your radar. Gate's got solid options for tracking these if you want to add them to your portfolio.